Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Do you have any clinical experience regarding the administration of B cell depleting therapies in MS patients with splenectomy?
Related Questions
What are red flags in an evaluation for possible multiple sclerosis that should prompt workup for genetic/inherited conditions?
How do you counsel women on anti-CD20 therapy for MS who are planning for pregnancy?
When do you offer high-dose vitamin D for patients with multiple sclerosis with normal serum levels?
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
What is the role of skin biopsy for evaluating small fiber neuropathy in patients with rheumatic disease who have treatment recalcitrant pain?
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?
How do you interpret conflicting findings on CSF immunoglobulin tests for work up of multiple sclerosis and its mimics?
What biomarkers best predict the response to B-cell depleting therapies in MS?
What are your vaccine recommendations while patients are on biologics?
